Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi Pasteur MSD S.N.C
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine
To describe the Seroprotection rate (SPR) at least 2 years following completion of a primary series of modified process RECOMBIVAX HB™ ( HBVaxPRO) and 1 month following a challenge dose of modified pr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of age
1. To show, that when HEXAVAC® upgraded process is given in a 3-dose primary series at 2, 4 and 6 months of age, followed by a booster dose at 12 months the anti-HBs seroprotection rate one month post...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when administered to Children in their Second Year of Life
To describe the safety profile of a second dose of ProQuad® manufactured with rHA when administered to children in their second year of life
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older
To demonstrate that a booster dose of Tdap-IPV vaccine is as immunogenic as a booster dose Tetanus monovalent vaccine in terms of anti-tetanus seroprotection rate (defined as percentage of subjects wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A study to compare immune response of V503 to Gardasil in 16- to 26-year-old men
The primary objective is to demonstrate that administration of the 9vHPVvaccine induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL® in 16- to ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-olds)
To demonstrate that administration of the 9-valent HPV L1 VLP vaccine induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 16 and anti-HPV 18 compared to GARDASIL in preadolescent and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal or over 70 years of age
To demonstrate that a second dose of ZOSTAVAX elicits higher varicella-zostervirus (VZV) antibody titers than first dose of ZOSTAVAX whether given a 0-1 month schedule or as a 0-3 month schedule in su...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2